-+ 0.00%
-+ 0.00%
-+ 0.00%

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

Barchart·07/22/2026 06:30:00
Listen to the news

- PDUFA target action date of May 8, 2027

- If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.